UNSPSC 51162641: Oxeladin

This classification denotes an antitussive agent with the molecular formula C20H33NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) SNC1080T5Y, chemically known as 2-(2-diethylaminoethoxy)ethyl alpha,alpha-diethylphenylacetate but more generally known as oxeladin, which bears US NIH Compound Identifier 4619. European Medicines Agency schedules Oxeladin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09513MIG.

UNSPSC 51162641 Oxeladin is a Commodity code representing pharmaceutical products procured by state and local governments for community health and emergency response initiatives. The recent solicitation activity shows state and local buyers seeking naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals including over-the-counter products. Issuing bodies under this code include county health departments (Seminole County, Florida) and state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). The work involves establishing supply contracts for pharmaceutical products with quarterly or ongoing delivery schedules, compliance with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and detailed product coding and tracking through authorized wholesalers. Vendors must maintain specific insurance coverage, including commercial general liability and professional liability, and comply with FDA requirements and expiration-date standards (at least one year from manufacture with six-month minimum shelf life).

Activity under this code spans Florida and Minnesota, with MMCAP's multi-state cooperative purchasing vehicle extending coverage to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities. Both solicitations require electronic bidding submission, detailed product information with National Drug Codes and SKUs, and vendor compliance with drug-free workplace certification and E-Verify requirements. MMCAP's contract term is two years for new vendors with optional extensions, while Seminole County's initial term is two years with a one-year renewal option and a three-month probationary period.